Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

CytoReason’s AI-Driven Disease Model Platform Trusted By 5 Top 10 Pharma Companies Harnesses Big Data To Speed Drug Discovery And Development

OurCrowd

By Meg Flippin, Benzinga Click here to learn more about CytoReason and how to invest through OurCrowd. Big data is transforming everything from the way we drive to the way we shop or even the way we consume energy. But when it comes to healthcare and fighting diseases, it still takes 10 or more years to bring a drug or treatment to market. What’s more, 90% of drugs in development fail. A big reason is that all the disparate data being collected from doctors, hospitals, clinical trials and patient outcomes reside in silos – thus not functioning together, and that only seems poised to get worse. The volume of human molecular data is growing rapidly, but analytic capabilities aren’t keeping up. That is essentially slowing progress in finding potential cures and more effective treatments. To overcome this challenge, a platform that can digest, organize and make sense of all the different data types and sources is needed – and that’s where CytoReason and its Disease Model Platform come in. Founded in 2016 to address this problem, CytoReason created what the company says is the first AI model to map treatments, patient groups and disease mechanisms while constantly evolving and learning. Bringing It All Together Researchers of all levels can rely on CytoReason’s proprietary data and innovative technology to make data-driven decisions across the drug development life cycle. Scientists can identify potential targets, prioritize indications, and stratify patient populations. Program leaders can compare drugs across multiple diseases or multiple drugs within a single disease. C-level executives can gain valuable tools to manage and optimize entire drug portfolios. Never before has there been that much data organized and analyzed on one platform, says CytoReason. Similar to how navigation apps provide layers of data about streets, buildings and addresses, CytoReason's Disease Model Platform offers layers of pre-computed data, which can include results from clinical trials, data on proteins and single-cell data. With multiple models for various diseases, users of the platform can identify potential targets, prioritize treatments, stratify patients and find possible drug combinations. User-generated data can also be integrated, and hypotheses across different treatments can be tested. The platform learns with you and can help you understand the cause of the disease and identify potential R&D avenues for prevention. Giving Pharma An Edge For drug development companies and researchers, CytoReason says the biggest advantage of its Disease Model Platform is its ability to compare assets across different diseases. With a single standard for all disease models, users can answer critical questions including which patients may benefit most from the drug, what other diseases the drug can be developed for, and how the drug stacks up against the drugs currently available. By answering those questions, decision-makers in pharma and biotech companies can find new opportunities, increase success rates and shorten the drug development cycle. Sounds too good to be true? The platform is already being used by five of the top ten pharma companies including Sanofi SA (NASDAQ: SNY), Pfizer Inc. (NYSE: PFE). Sanofi, which tapped CytoReason’s AI platform for use in the field of inflammatory bowel disease (IBD) expanded its multiyear collaboration last year. Sanofi is using the platform to identify patient subtypes and pair them with IBD targets. Under the terms of the expanded agreement, Sanofi will pay CytoReason an undisclosed multimillion-dollar amount. Pfizer, which has been working with CytoReason since 2019, also extended its collaboration, announcing in 2022 that it committed a $20 million equity investment, has options to license CytoReason’s platform and disease models and fund supplementary project support in a deal potentially worth up to $110 million over the next five years. Since the two began collaborating, Pfizer has used CytoReason's biological models in its research to enhance the understanding of the immune system as it develops innovative drugs for immune-mediated and immuno-oncology diseases. CytoReason's platform has provided Pfizer with multiple insights in its research and development programs across over 20 diseases. CytoReason’s platform has also benefited Poolbeg Pharma, which has been using it to find novel approaches for treating influenza. Poolbeg’s disease progression data from influenza human challenge trials combined with CytoReason’s disease model platform led to the discovery of multiple novel drug targets for the treatment of influenza. Big data is growing exponentially, particularly in the healthcare field, but getting it under one roof has proven difficult. It's the reason it takes so long to develop drugs and why the majority of them fail. Platforms like CytoReason are working to change that, providing AI-generated insights to understand disease mechanisms and disease progression, as well as potential treatment methods. In a world where data is endless, CytoReason is making sense of it all. To learn more about CytoReason and its novel approach to data click here. OurCrowd was started in 2013, driven by the idea that the business of building startups grows bigger and better when the global ‘crowd’ gains access to VC-level investment opportunities.Today, OurCrowd is a global venture and alternative investing platform that empowers institutions and individuals to invest and engage in emerging companies. OurCrowd vets and selects companies, invests its capital, and provides its global network with unparalleled access to co-invest and contribute connections, talent and deal flow. OurCrowd builds value for its portfolio companies throughout their lifecycles, providing mentorship, recruiting industry advisors, navigating follow-on rounds and creating growth opportunities through its network of multinational partnerships. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Lisa Graston lisa.graston@ourcrowd.com Company Website http://www.ourcrowd.com

February 06, 2024 08:10 AM Eastern Standard Time

Exciting Transition as Executive Director Prepares for New Chapter

National Contract Management Association

The NCMA Contract Management Institute (CMI) announces that Soraya Correa, who has served as the dedicated Executive Director for the past year, will be joining the team at National Industries for the Blind as their new President and CEO-Elect. Ms. Correa will be transitioning into a governance role, maintaining a crucial connection with CMI and its strategic direction. This shift reflects her continued dedication to the institute's mission and the desire to contribute to its future success at a governance level. Kraig Conrad, CEO of NCMA and Chair of the CMI Governance Board, "We express our gratitude for the invaluable contributions Soraya has made to the relaunch of the Contract Management Institute. Her enduring legacy is marked by a steadfast commitment to remaining actively engaged in the NCMA community and continuing her involvement in the governance of CMI." Amid expressions of gratitude for her contributions, Ms. Correa reflected on her time at the Institute, underscoring the impact she has had on its relaunch, community engagement, and governance. “While I am excited about this new opportunity with the National Industries for the Blind (NIB), I am sad to leave CMI. As Executive Director of CMI I had the opportunity to work with the outstanding leadership, team, and members of NCMA, an experience I will always appreciate and remember fondly. I remain committed to the success of CMI and the vital role it plays in advancing the contract management profession. As I embark in my new role at NIB, I will continue to support NCMA initiatives, especially those of the CMI!” In the interim, taking over the Executive Director position for CMI will be Mr. Conrad. Stay tuned for more updates and CMI’s research projects begin this Spring. For inquiries and paper submissions, please contact info@ncmahq.org. The Contract Management Institute (CMI) is a leading professional organization dedicated to advancing the field of contract management. With a mission to drive innovation, promote excellence, and enhance the role of the contracting professional, CMI provides valuable resources including collaboration and partnership opportunities for individuals and organizations involved in contract management across government, industry, and academia. The Institute serves as a catalyst for the study of the profession to elevate engagement, standards, and professional development. The CMI mission and vision are aligned with its parent, NCMA. CMI is a 501(c)(3) charitable organization. The National Contract Management Association (NCMA) - www.ncmahq.org - stands as the premier contract management organization whose mission is to collaborate towards a globally recognized contract management profession that strengthens its nexus with related acquisition communities. Serving approximately 20,000 members in both the public and private sectors, NCMA propels the growth, advancement, and impact of practitioners through a steadfast commitment to serve through the open exchange of ideas in neutral forums. Contact Details NCMA Holly DeHesa +1 281-865-3296 holly.dehesa@ncmahq.org Company Website https://www.ncmahq.org

February 05, 2024 07:05 PM Eastern Standard Time

Clene Inc. announces positive results from CNM-Au8 results from MS trial

Clene Inc

Clene Inc (NASDAQ:CLNN) CEO Rob Etherington joined Steve Darling from Proactive to share news regarding the latest findings from the long-term open-label extension (LTE) of the VISIONARY-MS trial. This trial focuses on participants with stable relapsing multiple sclerosis (MS) and represents nearly three years of follow-up research. Following the conclusion of the double-blind period of the trial, participants were given the opportunity to continue with CNM-Au8® treatment at a dose of 30mg for an additional 96 weeks during the LTE phase. The analysis encompassed the modified intent-to-treat population, which included all study participants with valid clinical data. Etherington highlighted the key finding that long-term CNM-Au8 treatment showcased improvements in vision, as measured by low contrast visual acuity, an essential assessment of visual function in individuals living with multiple sclerosis. Remarkably, these improvements in vision persisted for 35 months from randomization, demonstrating the sustained efficacy of CNM-Au8 over an extended period. Moreover, the data revealed consistent and robust overall enhancements not only in vision but also in cognition among participants treated with CNM-Au8 for nearly three years from randomization. These results are particularly noteworthy for their potential to positively impact disease progression and potentially reverse established disability, representing a significant therapeutic breakthrough for patients with MS. Full clinical results from the long-term open-label extension will be officially presented at the ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis Forum, scheduled to take place from February 29 to March 2, 2024, in West Palm Beach, Florida. Clene's commitment to advancing treatments for multiple sclerosis is evident in these promising results, and their ongoing research holds great promise for enhancing the quality of life for individuals affected by this condition. The potential to offer effective long-term solutions and improve both vision and cognitive function is a significant step forward in the battle against multiple sclerosis. Contact Details Proactive Canada Proactive Canada +1 604-688-8158 action@proactiveinvestors.com

February 05, 2024 02:30 PM Eastern Standard Time

Video

LungLife AI announces success in Validation of LungLB in multi-site, prospective clinical study

LungLife AI Inc

LungLife AI CEO Dr. Paul Pagano joined Steve Darling from Proactive to discussed the groundbreaking lung cancer detection technology developed by the company. LungLife AI is dedicated to addressing the critical issue of early detection in lung cancer, which remains the leading cause of cancer-related deaths. Dr. Pagano highlighted the sobering statistic that 80% of lung cancer cases are detected too late, contributing to the high mortality rate associated with this disease. The company's lung lb test, which has recently undergone successful validation, is poised to revolutionize the early detection of lung cancer by addressing the challenge of evaluating small nodules under 15 millimetres in size. Early intervention is crucial in improving patient outcomes, and the lung lb test is designed to meet this unmet need. Physicians have expressed excitement about the potential of this test to transform the landscape of lung cancer detection. Unlike existing methods, the lung lb test takes a unique approach by examining circulating genetically abnormal cells in the blood. This innovative approach offers a complementary and highly sensitive means of detecting lung cancer, enhancing the chances of early intervention and improved patient prognosis. Dr. Pagano discussed the competitive landscape, emphasizing LungLife AI's patented methods and proprietary technologies that set their approach apart in the field of lung cancer detection. Looking ahead, LungLife AI plans a methodical introduction of the lung lb test through an early access program, ensuring a seamless transition into healthcare settings. The next six to twelve months will involve a commercial proof of concept, with the company collaborating with hospital sites and working towards securing coverage from insurance providers. The potential life-saving impact of LungLife AI's technology and their strategic approach to making it accessible to patients and healthcare providers mark a significant contribution to advancing the field of lung cancer detection. The company's dedication to improving early detection rates and ultimately reducing the mortality associated with this devastating disease underscores their commitment to patient care and well-being. Contact Details Proactive UK Ltd Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

February 05, 2024 02:25 PM Eastern Standard Time

Video

Flora Growth Corp's CEO Reveals Record-Breaking Financials and Exciting 2024 Plans

Flora Growth Corp

Flora Growth CEO Clifford Starke joined Steve Darling from Proactive to share exciting news about the company's remarkable financial performance and its strategic plans for the future. Flora Growth is a diversified company with three main pillars, and it recently reported its best-ever financial results. Starke highlighted Flora's three core pillars, Vessel which is a rapidly growing brand with widespread distribution, the CBD Gummy Division, and Fatima a pharmaceutical company based in South Germany. The company recently went under strategic restructuring, which included the sale of an unprofitable Colombian entity and streamlining its team, which led to a net income of $1.1 million in the last quarter. The success of the last quarter is attributed to these strategic decisions, setting the stage for a promising 2024. Looking ahead, Flora Growth plans to enter the rapidly growing US beverage market by launching a product called Mellow in Q1. Leveraging its strong distribution network, the company aims to capitalize on the untapped potential in the beverage segment. Starke emphasized the importance of continuous product innovation, hinting at upcoming releases in 2024 that will compete with established brands in the dry herb space. As Flora Growth anticipates a record-breaking year, Starke highlighted their commitment to product innovation and strategic expansion, positioning the company as one to watch in the cannabis industry. Contact Details Proactive United States Proactive United States +1 347-449-0879 action@proactiveinvestors.com

February 05, 2024 01:03 PM Eastern Standard Time

Video

Speak And Be Saved: App Detects Heart Failure Weeks Before Attack

OurCrowd

By Jeremy Ruden “The puppy sat on the ship.” That was one of five potentially life-saving sentences that heart patients spoke into their smartphones during a US trial for HearO, the groundbreaking app that detects signs of congestive heart failure (CHF) simply by monitoring a person’s voice. Created by startup Cordio Medical, the system’s artificial intelligence algorithms detect voice changes that indicate fluid accumulation in the lungs before any symptoms surface. When changes are noticed, the system alerts the patient’s doctor of an imminent risk that might require medication, IV therapy or hospitalization, allowing intervention before the condition deteriorates. The company is currently raising a funding round via OurCrowd, the Jerusalem-based investment platform that allows accredited investors to access privately held startups. In trials, the HearO app successfully predicted heart failure in 81% of cases, about three weeks before heart failure actually occurs, giving physicians time to intervene and scale back expensive and traumatic hospitalizations. The condition develops when the heart muscle is too weak to pump all the blood the body needs. Fluid builds up in the extremities and lungs as a result. “This approach has the potential to reduce acute decompensated heart failure hospitalizations and improve patient quality of life and economic outcomes,” says William T. Abraham, MD, of Ohio State University Wexner Medical Center in Columbus, who reported the trial findings at the 2023 Scientific Sessions of the American Heart Association. The app functions by having patients record a baseline of phrases when their lungs are clear, then repeat them daily so algorithms can detect any changes. Saving lives With over 26 million people in the Western world suffering from CHF, the need to monitor patients is growing quickly. About half are at high risk of a fatal incident within five years of diagnosis. CHF patients generally require timely, personalized medical attention to avoid episodes that demand immediate medical care or hospitalization. Prevalence of CHF in the US alone is projected to increase by nearly 50% by 2030, while direct medical costs – predominantly hospitalization – are forecast to more than double between 2012 and 2030. The annual burden of CHF on the US healthcare system is some $18 billion. “The holy grail” of the heart failure monitoring industry “is to find a solution that will help a patient know in advance when they’re deteriorating so they can change their diuretics and hopefully avoid hospitalization,” says Tamir Tal, CEO of Cordio Medical. In the long run, Cordio plans to use the technology to detect other conditions such as chronic obstructive pulmonary disease, Tal says. The company is initially targeting heart failure, which frequently causes patients to return to the hospital for lengthy, expensive stays. “Speech carries a lot of personal information about us. When you talk to your mom, just one sentence is enough for her to know how you feel,” says Tal. “We might not be giving the same kind of support as a parent, but we are using speech to give the physician something they can objectively use to determine a patient’s medical condition, helping them avoid serious health episodes.” AstraZeneca partnership In the US, Cordio Medical’s DETECT-HF pivotal study is fully operative, with data collected from dozens of patients in 38 centers. As a result of the clinical collaborations with the centers, the company has already received commercial interest from participants. This extensive collaboration with renowned medical centers has the potential to establish a smooth pathway for future commercial traction. Some of the largest US providers and payers are among the members of the pivotal steering committee, a further sign of their faith in HearO’s clinical significance and business potential. In Europe, Cordio found a partner in pharma giant AstraZeneca. In Q3 2023, the two companies began a second pilot program in Spain at the General Hospital of Valencia in conjunction with the Valencian Society of Cardiology. The first ongoing pilot is being conducted at Bellvitge University Hospital. “AstraZeneca is committed to advancing digital tools to diagnose, monitor and treat high-impact pathologies such as heart failure,” says César Velasco, director of Innovation and Digital Strategy at AstraZeneca. “Thanks to the collaboration across Spanish hospitals and health professionals, we are closer to making life-saving digital health tools a reality for millions with chronic diseases. FDA approval The HearO system received a prestigious and coveted Breakthrough Device designation from the FDA, with approval for the CHF indication forecast in Q1 2025, around 6 months after the company is expected to complete and publish the data from the US pilot. In the EU, Cordio obtained the CE certificate for HearO’s software application. The system was also approved by the Israeli Health Ministry. Cordio has several key investors including Peregrin, Ceros, Aegis Capital and Super-Pharm. They are all participating in the company’s current SAFE, which is available to accredited investors via OurCrowd. For more information about investing in Cordio Medical via OurCrowd, click HERE. OurCrowd was started in 2013, driven by the idea that the business of building startups grows bigger and better when the global ‘crowd’ gains access to VC-level investment opportunities.Today, OurCrowd is a global venture and alternative investing platform that empowers institutions and individuals to invest and engage in emerging companies. OurCrowd vets and selects companies, invests its capital, and provides its global network with unparalleled access to co-invest and contribute connections, talent and deal flow. OurCrowd builds value for its portfolio companies throughout their lifecycles, providing mentorship, recruiting industry advisors, navigating follow-on rounds and creating growth opportunities through its network of multinational partnerships. Contact Details Lisa Graston lisa.graston@ourcrowd.com Company Website http://www.ourcrowd.com

February 05, 2024 08:45 AM Eastern Standard Time

Video Image

Comcast Expanding Network in Minnesota

Comcast Twin Cities

Comcast announces expansions of its smart, fast, reliable fiber-rich network to seven new cities in Minnesota by the end of 2024. The cities of Corcoran, Cologne, Nowthen, and parts of Grant, Hugo, Rogers and Stillwater Township will see 5x-10x faster upload speeds and smoother connections with the Xfinity Network. The 2024 planned expansion is part of the company’s nationwide rollout of multi-gig Internet speeds and adds to Comcast’s ongoing $473 million investment across Minnesota over the last three years. The new planned expansions fulfill a need for fast, reliable, secure broadband service across the state. In June 2023, Comcast completed an expansion to more than 2,300 homes and businesses in the City of Wayzata. Area businesses enjoy broadband speeds of up to 100 Gbps and speeds faster than 1 gigabit per second for residents over standard connections in the home. By the end of 2024 Comcast will also expand into Cologne and extend its network into Nowthen, Corcoran, and throughout parts of Rogers, Grant, Hugo and Stillwater Township with funding support from the State of Minnesota’s Border-to-Border Broadband program. “Access to reliable, high-speed broadband is a powerful driver of economic growth and development in our community,” said Corcoran Mayor Tom McKee. “Internet access is at the center of our modern lives and the quality of those lives will be greatly enhanced thanks to the partnership with Comcast, Hennepin County and the Minnesota Office of Broadband. Together we will be bringing broadband to nearly 500 unserved homes and businesses in Corcoran.” These locations will have the foundational next-generation network in place to begin deploying DOCSIS 4.0, setting the stage for the introduction of new symmetrical multi-gigabit Internet options that will enhance performance across Comcast’s existing networks. “The Internet has increasingly become the epicenter of our existence, influencing many aspects of our lives, and people and businesses are consuming more data,” said Kalyn Hove, Senior Vice President, Comcast Midwest Region. “We are building a future of unlimited possibilities in the Twin Cities and across the Midwest. These expansions, plus planned networks enhancements, will service nearly 14,000 additional homes.” Powered by Xfinity Comcast’s network and Internet experience are powering homes and businesses today and into the future: Ultimate Capacity: Xfinity customers connect more than 1 billion devices across the company’s network annually. With the next-generation Xfinity gateways we deliver the most advanced WiFi technology carrying three times more bandwidth to power streaming, gaming, videoconferencing, and more, simultaneously. Fastest Internet: More than a third of Xfinity Internet customers subscribe to gigabit speed products. Recently, Comcast connected the first customers in the world to a DOCSIS 4.0 connection, delivering symmetrical gig speeds over existing connections in customers’ homes with plans to continue to rollout these speeds across the country, including the Twin Cities, over the coming years. Unprecedented Coverage: The latest Xfinity Gateway provides a more reliable connection throughout the home. Customers can get wall-to-wall WiFi coverage with a powerful WiFi Boost Pod that extends coverage to hard-to-reach areas of the home. Most Reliable Connection: Comcast is scaling the nation’s largest and most reliable network that passes 62 million homes and business and counting. The company launched Storm-Ready WiFi, a new device that comes powered with cellular and battery backup to help keep customers connected even when the power goes out. Ultra-Low Latency: The Xfinity Network and the latest Xfinity Gateway are a powerful combination that deliver ultra-low latency for those moments when response times matter most like video games, a fast-growing category with Xfinity households averaging more than one gaming console per home. The Xfinity Network is also self-monitoring and uses AI to detect potential problems before they arise, delivering a reliable connection that is up and running in customers’ homes 99% of the time. Visit Xfinity to learn more and sign up for these exciting new products. About Comcast Corporation Comcast Corporation (Nasdaq: CMCSA) is a global media and technology company. From the connectivity and platforms we provide, to the content and experiences we create, our businesses reach hundreds of millions of customers, viewers, and guests worldwide. We deliver world-class broadband, wireless, and video through Xfinity, Comcast Business, and Sky; produce, distribute, and stream leading entertainment, sports, and news through brands including NBC, Telemundo, Universal, Peacock, and Sky; and bring incredible theme parks and attractions to life through Universal Destinations & Experiences. Visit www.comcastcorporation.com for more information. Contact Details Jill Hornbacher +1 651-425-1695 Jill_Hornbacher@comcast.com Company Website https://midwest.comcast.com/

February 05, 2024 07:00 AM Central Standard Time

Image

22nd Century Group CEO Larry Firestone: Transforming Tobacco Industry with FDA-Approved VLN Brand

22nd Century Group Inc

22nd Century Group new CEO Larry Firestone joined Steve Darling from Proactive to discuss his role and the company's strategic direction. 22nd Century Group is an agricultural biotech firm specializing in tobacco harm reduction and developing low-nicotine content plants for cigarettes. Notably, the company received FDA authorization for modified risk tobacco products in December 2021, with its flagship brand, VLN (Very Low Nicotine), aimed at addressing smoking-related health issues. Firestone emphasized the strategic shift the company is undergoing, which includes streamlining operations, divesting non-core assets such as the hemp cannabis business, and refocusing solely on the tobacco sector. The company's primary goal for 2024 is achieving financial self-sustainability, with a focus on cost optimization, gross margin improvement, and streamlining the overhead structure. 22nd Century Group is also committed to expanding its presence in established markets, particularly in the United States, and delivering its core products. Firestone's leadership will play a crucial role in guiding the company through these transformative changes and positioning it for growth and success in the coming years. This strategic shift and renewed focus on tobacco harm reduction reflect 22nd Century Group's commitment to addressing health-related issues associated with smoking and its determination to make a positive impact in the tobacco industry. Contact Details Proactive United States Proactive United States +1 347-449-0879 action@proactiveinvestors.com

February 05, 2024 07:29 AM Eastern Standard Time

Video

2 Million Cancer Diagnoses And 600,000 Cancer Deaths Expected In 2024 – Prevention Is Key To Treatment, And Mainz Biomed Is Leading The Charge

Benzinga

By Faith Ashmore, Benzinga The global population is experiencing a scary increase in colorectal cancer, especially among young people. Colorectal cancer (CRC) diagnoses have been steadily rising since the 1990s; in 1995 the proportion of these cancer cases in adults younger than 55 was 11%, and in 2019, the number was 20%. It is recommended that adults start screening for colorectal cancer at age 45 but with the increase in prevalence, the value of early detection cannot be understated. While doctors still aren’t sure of the reason behind this increase, they are urging the public to take these numbers seriously and embrace preventative measures for early detection. Companies like Mainz Biomed (NASDAQ: MYNZ), a company that specializes in developing molecular genetic diagnostic solutions for life-threatening conditions, are leading the charge in helping make that happen. This company has created ColoAlert®, an innovative product that addresses the need for easier and more accessible cancer screenings for quick detection and treatment of colorectal cancer. The non-invasive and user-friendly test aims to make colorectal cancer screening fast, simple and precise. Once launched in the U.S. Mainz Biomed's ColoAlert will compete with Cologuard from Exact Sciences Corporation (NASDAQ: EXAS), a well-established company that commands a market cap of over $10 billion. The key difference between Cologuard and ColoAlert is that ColoAlert requires far less stool collection than its competitor, a testament to ColoAlert’s technology. This not only increases convenience for the patient but also cuts down on shipping costs and lab time. The only other detection model outside of a traditional colonoscopy is a blood-stool test; however, these tests can only detect cancer, not pre-cancerous polyps. Mainz Biomed has partnered with Liquid Biosciences to ensure its cutting-edge products are top-of-the-line. Recently, Mainz Biomed conducted a multi-center international clinical trial in Germany and Norway to evaluate the effectiveness of incorporating mRNA biomarkers into ColoAlert®. The study yielded impressive findings, demonstrating a high sensitivity of 94.4% and specificity of 97.5% for detecting CRC. Additionally, the screening test showed a sensitivity of 80% and specificity of 95.2% in detecting precursor lesions, including advanced adenomas that may develop into CRC. In other words, ColoAlert is designed to detect pre-cancerous polyps as well as identify individuals who have colorectal cancer. The CDC reports that colorectal cancer is the second most fatal cancer in the United States and Europe. However, it is also the most preventable, with early detection leading to survival rates above 90%. ColoAlert can be instrumental in preventive care for colorectal cancer. The company reports it has experienced success in Germany, where the product is available through labs, industry partnerships and online for purchase. In 2024, Mainz Biomed is looking to replicate this success in the U.S. and is planning to launch a pivotal trial, seeking FDA approval for its product. If successful, the company will look to partner with a network of labs across the country to increase accessibility to its product with the hope that more Americans will be able to detect pre-cancerous polyps before it is too late. With the American Cancer Society predicting over 600,000 cancer deaths and the equivalent of 5,000 cancer diagnoses each day in 2024, prevention is key to treatment. The preventive healthcare market has gotten a lot of attention in recent years, and it is expected to reach $415 billion by 2031 with a CAGR of 9.7% from 2024 to 2031. Mainz Biomed’s ColoAlert is a great example of the power of technology that can screen for pre-cancerous markers. Mainz Biomed's dedication to pushing the limits of diagnostic technology, enhancing accessibility and its growth trajectory potentially establish it as a formidable presence in the industry, setting it apart from its competitors. Featured photo by Artur Tumasjan on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

February 02, 2024 08:35 AM Eastern Standard Time

Image

1 ... 57 58 59 60 61 ... 304